



Kaletra[®] (lopinavir/ritonavir) – First-Time Generic

- On January 15, 2017, Lannett launched an [AA-rated](#) generic version of AbbVie's [Kaletra \(lopinavir/ritonavir\)](#) oral solution for the treatment of HIV-1 infection in adults and pediatric patients (≥ 14 days old) when used in combination with other antiretroviral agents.
 - The use of other active agents with Kaletra is associated with a greater likelihood of treatment response.
 - Genotypic or phenotypic testing and/or treatment history should guide the use of Kaletra. The number of baseline lopinavir resistance-associated substitutions affects the virologic response to Kaletra.
- Kaletra is currently available as a branded tablet formulation which carries the same indication as the oral solution.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.